Information Provided By:
Fly News Breaks for February 21, 2020
Feb 21, 2020 | 07:35 EDT
Cantor Fitzgerald analyst Craig Bijou raised the firm's price target on NuVasive to $85 from $68 and keeps a Neutral rating on the shares. The analyst says NuVasive introduced 2020 guidance in-line with consensus but that the Pulse launch delay is disappointing as it puts the company further behind competitors that already have enabling technologies on the market. He prefers to remain on the sidelines until seeing how NuVasive executes to start the year.